Real-life experience with benralizumab during 6 months

Real-life experience with benralizumab during 6 months

Abstract Background Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, suf...

Full description

Bibliographic Details
Main Authors: A. Padilla-Galo, RCh Levy-Abitbol, C. Olveira, B. Valencia Azcona, M. Pérez Morales, F. Rivas-Ruiz, B. Tortajada-Goitia, I. Moya-Carmona, A. Levy-Naon
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Pulmonary Medicine
Subjects:
Asthma
Benralizumab
Eosinophils
Biologics
Severe asthma
Eosinophilic asthma
Online Access:http://link.springer.com/article/10.1186/s12890-020-01220-9

Internet

http://link.springer.com/article/10.1186/s12890-020-01220-9

Similar Items